

Onderzoeksinfrastructuur

voor COVID-19 behandeling



@Lennie333



Lennie Derde



lennie.derde




UMC Utrecht


(potentiële) belangenverstrengeling	
Voor bijeenkomst mogelijk relevante relaties met bedrijven	medicatie REMAP-CAP trial Roche Products Ltd Sanofi (Aventis Pharma Ltd) Swedish Orphan Biovitrum AB (Sobi™) Faron Pharmaceuticals
Sponsoring of onderzoeksgeld	ZonMw (ANACOR-IC; projectnr 10150062010003) FP7-HEALTH-2013-INNOVATION-1 (PREPARE; #602525) Horizon 2020 research and innovation program (RECOVER; #101003589)
Honorarium of andere (financiële) vergoeding	ISAB en RMC voor Sepsis Canada (onkosten) <i>speakers fee</i> ERS, Netherlands International Sepsis Symposium



Pandemic influenza studies registered in clinical trials database




Adapted from Rojek et al., BMC Med (2020); 18(1), 265







SARS outbreak 2002-2003




COVID-19 outbreak 2019-2020







▼ Sample size


















Lancet Infect Dis 2021 Dec 21;S1473-3099(21)00705-2


Lancet Infect Dis 2022; 22(3):315

Lancet Infect Dis 2022; 22(3):315–316



funding


PEARL hurdles



Berry, SM et al *JAMA* 2015;313(16):1619-1620


Angus, DC *JAMA* 2015;314(8):767-768

The APT Coalition, *NRDD* 2019;18:797–807




Superiority

Inferiority




Superiority

Inferiority




Superiority

Inferiority



Superiority

Inferiority





Conclusie	Resultaat	Publicaties
Corticosteroiden	Benefit	<i>JAMA</i> 2020;324(13):1317-1329 <i>JAMA</i> 2020;324(13):1330-1341 <i>BMJ</i> 2020;370:m3379 (first version)
Lopinavir/ritonavir Hydroxychloroquine	Likely harm Harm	<i>ICM</i> 2021 Aug;47(8):867-886 <i>Nature Comms</i> 2021; 12: 2349
Tocilizumab Sarilumab Anakinra Interferon beta-1a	Benefit Benefit Futile Operationally futile	<i>NEJM</i> 2021; 384(16):1491-1502 www.medrxiv.org/content/10.1101/2021.06.18.21259133v2 <i>JAMA</i> 2021;326(6):499-518 www.medrxiv.org/content/10.1101/2021.08.26.21262523v1
Heparin – moderate	Benefit	<i>NEJM</i> 2021; 385(9):790-802
Heparin – severe	Futile	<i>NEJM</i> 2021; 385(9):777-789
Convalescent plasma	Futile	<i>JAMA</i> 2021;326(17):1690-1702
Aspirine	Futile	<i>JAMA</i> Published online March 22, 2022 doi:10.1001/jama.2022.2910



The European Clinical Research Alliance on Infectious Diseases

ecraid

Purpose driven, people centred

www.ecraid.eu

 @Ecraid


 Ecraid

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 965313



Europe's single point of access clinical research network for infectious diseases

ECRAID-Prime								
Primary care	Hospitals	Long-term care	Pediatrics	LAB-Net	BIO-Net	EPI-Net	STAT-Net	
ECRAID-Base								
Primary care	Hospitals	Long-term care	Pediatrics	LAB-Net	BIO-Net	EPI-Net	STAT-Net	
RECOVER								
Primary care	Hospitals	Long-term care	Pediatrics	LAB-Net	BIO-Net	EPI-Net	STAT-Net	
VALUE-Dx								
Primary care	Hospitals	Long-term care	Pediatrics	LAB-Net	BIO-Net	EPI-Net	STAT-Net	
PREPARE								
Primary care	Hospitals	Long-term care	Pediatrics	LAB-Net	BIO-Net	EPI-Net	STAT-Net	
COMBACTE								
Primary care	Hospitals	Long-term care	Pediatrics	LAB-Net	BIO-Net	EPI-Net	STAT-Net	



Pandemic Research Preparedness

*infrastructuur
slimme designs
prioriteren*

onderzoekers – funders – regulators



@Lennie333



Lennie Derde



lennie.derde